New pharmacologic therapies in chronic hepatitis B.
Approximately 350 million persons worldwide are chronically infected with hepatitis B, which can result in cirrhosis, liver failure, and hepatocellular carcinoma. Currently, 2 interferons and 5 nucleos(t)ide analogues have been approved for the treatment of chronic hepatitis B (CHB). This article discusses the mechanisms of action, pharmacokinetics, optimal dose, clinical efficacy, and side effects of medications used for the treatment of CHB.
Division of Gastroenterology, University of Michigan, 3110G Taubman Center, 1500 East Medical Center Drive, SPC 5362, Ann Arbor, MI 48109, USA.
Chanunta
C
Hongthanakorn
Anna S F
AS
Lok
D000998:Antiviral Agents / Q000494:pharmacology* / Q000627:therapeutic use; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D007372:Interferons / Q000494:pharmacology* / Q000627:therapeutic use; D009705:Nucleosides / Q000494:pharmacology* / Q000627:therapeutic use; D009711:Nucleotides / Q000494:pharmacology* / Q000627:therapeutic use; D011092:Polyethylene Glycols / Q000494:pharmacology / Q000627:therapeutic use; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use
D000998:Antiviral Agents; D009705:Nucleosides; D009711:Nucleotides; D018894:Reverse Transcriptase Inhibitors; D011092:Polyethylene Glycols; D007372:Interferons